US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

19.14

-0.2098-1.08%

Post-market: 19.140.00000.00%19:30 EDT

Volume:127.96K

Turnover:2.44M

Market Cap:112.91M

PE:- -

High:19.20

Open:19.04

Low:18.87

Close:19.35

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:2.99

T/O Rate:2.17%

Dividend:0.71

Dividend Rate:3.73%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CSPC Pharmaceutical Group Stock Sheds 3.0% in Hong Kong, Underperforms Competitors

WuXi Biologics' Stronger Project Backlog Could Underpin Revenue Visibility

Akeso, Inc. (HKG:9926) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.

WuXi XDC Files HKEX Next-Day Disclosure Return, Lifts Share Capital by 1,707,842 Shares

China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices

China's Joinn Laboratories H1 Profit Jumps 1,127% on Strong Drug Demand

Hong Kong's Frontage Holdings H1 Profit More than Doubles on Teddy Lab Acquisition

CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors

Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

CMB International Lifts WUXI BIO Price Target to HK$60, Maintains "Buy" Rating

Akeso's Losses Narrow in H1 as Revenue Climbs 28%

MT Newswires Live

Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Simply Wall St.

Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy

MT Newswires Live

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/KURE/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":19.14,"timestamp":1790971200000,"preClose":19.3498,"halted":0,"volume":127957,"hourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010842489328054955,"floatShares":5899036,"shares":5899036,"eps":0,"marketStatus":"Market Closed","change":-0.2098,"latestTime":"10-02 16:00:00 EDT","open":19.04,"high":19.2,"low":18.87,"amount":2436278.887525,"amplitude":0.017054,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.3498,"sharesOutstanding":4750002,"nav":19.06,"aum":112453199.16,"dividendRate":0.037315,"bidAskSpread":0.008807,"postHourTrading":{"tag":"盘后","latestPrice":19.14,"preClose":19.14,"latestTime":"19:30 EDT","volume":8,"amount":153.12,"timestamp":1790983803066,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.9854503635447447,"impliedVol":0.1722,"impliedVolPercentile":0.3665},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5899036,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.9854503635447447,"shares":5899036,"dividePrice":0.7142,"high":19.2,"amplitude":0.017054,"preClose":19.3498,"low":18.87,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":19.14,"eps":0,"divideRate":0.037315,"volume":127957,"delay":0,"ttmEps":0,"open":19.04,"prevYearClose":17.04,"prevWeekClose":18.72,"prevMonthClose":19.25,"prevQuarterClose":19.25,"fiveDayClose":18.72,"twentyDayClose":18.91,"sixtyDayClose":16.4655},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663073038","title":"CSPC Pharmaceutical Group Stock Sheds 3.0% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2663073038","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663073038?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:32","pubTimestamp":1788165120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slipped 3.0% to 9.24 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.1% to 25566.99.This was the stock's second consecutive day of losses.CSPC Pharmaceutical Group Ltd. closed 21% short of its 52-week high of HK$11.63, which the company reached Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 2.6%, SSY Group Ltd. rose 0.4%, and United Laboratories International Holdings Ltd. fell 3.4%.Trading volume totaled 136.5 million shares, compared to the 50-day average of 104.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951186391.HKD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1152091754.HKD","LU0072913022.USD","BK1521","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","LU0140636845.USD","LU1993786604.SGD","IE00BZ08YT58.USD","LU0326950275.SGD","BK1191","LU1226288170.HKD","LU1008478684.HKD","LU1813983027.USD","LU1328277881.USD","LU1226287875.USD","IE0008368742.USD","LU1226287792.SGD","LU1152091168.USD","LU1226287529.USD","BK1515","KURE","LU0880133367.SGD","LU1807302812.USD","LU0315179316.USD","IE00B031HY20.USD","LU1960683339.HKD","HK0000165453.HKD","LU0314109678.HKD","IE0008369823.USD","LU1226288253.USD","SG9999004220.SGD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663707395","title":"WuXi Biologics' Stronger Project Backlog Could Underpin Revenue Visibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2663707395","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663707395?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:13","pubTimestamp":1788163980,"startTime":"0","endTime":"0","summary":"0813 GMT - WuXi Biologics' stronger project backlog is likely to underpin its revenue visibility, says China Galaxy International Securities' Vicky Zhu in a note. The contract research, development and manufacturing company added 169 new projects and 119 net integrated projects in 1H, while its total revenue backlog reached US$25.1 billion as of end June, she notes. The acquisition of BioDlink also contributed to the higher number of projects, she adds. She raises her 2026-2027 revenue growth estimates to around 21% and lifts her 2026-2028 earnings per share estimates by 2%-8%. China Galaxy therefore raises its target price to HK$57.82 from HK$48.62 and maintains an add rating. Shares closed 3.6% lower at HK$48.84.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU0417516738.SGD","LU0140636845.USD","LU0181495838.USD","LU0516422366.SGD","SG9999002463.SGD","BK1610","LU0417516902.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0456846285.SGD","LU1242518857.USD","LU0823426308.USD","LU0708995583.HKD","SG9999002562.SGD","LU0819121731.USD","LU1794554557.SGD","LU1880383366.USD","LU0856984785.SGD","BK1576","LU0823426480.USD","BK1589","LU0348825331.USD","LU1242518931.SGD","LU0516423174.USD","LU0516422952.EUR","LU0516423091.SGD","LU0051755006.USD","LU0456827905.SGD","LU0029874061.USD","LU3063872942.SGD","LU0359201612.USD","BK1141","LU0327786744.USD","KURE","LU1688375341.USD","LU0307460666.USD","LU0326950275.SGD","LU0320764599.SGD","LU0348735423.USD","LU0516422440.USD","LU0588546209.SGD","LU2039709279.SGD","02269","LU0039217434.USD","BK1521","LU0128526141.USD","LU1720050803.USD","LU0572944931.SGD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663228310","title":"Akeso, Inc. (HKG:9926) Analysts Are Cutting Their Estimates: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2663228310","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663228310?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:40","pubTimestamp":1788140412,"startTime":"0","endTime":"0","summary":"Investors in Akeso, Inc. ( HKG:9926 ) had a good week, as its shares rose 5.7% to close at HK$95.35 following the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-inc-hkg9926-analysts-are-cutting-their-estimates-heres","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-inc-hkg9926-analysts-are-cutting-their-estimates-heres","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2476274308.USD","LU0540923850.HKD","LU0561508036.HKD","LU1720050803.USD","LU1961090484.USD","LU0348767384.USD","LU2399975544.HKD","LU2778985437.USD","LU0348735423.USD","LU0417516738.SGD","BK1161","IE00B543WZ88.USD","BK1574","LU0417516571.SGD","LU0348766576.USD","KURE","LU2488822045.USD","LU2476274720.SGD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348784397.USD","LU1794554557.SGD","IE00BPRC5H50.USD","09926","LU0348825331.USD","LU0348827113.USD","LU0417516902.SGD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662095555","title":"WuXi XDC Files HKEX Next-Day Disclosure Return, Lifts Share Capital by 1,707,842 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662095555","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662095555?lang=en_us&edition=fundamental","pubTime":"2026-08-28 21:12","pubTimestamp":1787922773,"startTime":"0","endTime":"0","summary":"WuXi XDC files HKEX next-day disclosure return, lifts share capital by 1,707,842 sharesWuxi XDC filed a next-day disclosure return showing 1,707,842 new ordinary shares issued from share option exerci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLYmvG5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU1880383366.USD","LU0359202008.SGD","KURE","LU0516423174.USD","LU0456846285.SGD","LU0181495838.USD","BK1141","LU1242518857.USD","LU1242518931.SGD","LU0708995583.HKD","LU0039217434.USD","BK1576","LU0128526141.USD","LU0348825331.USD","LU1720050803.USD","LU0327786744.USD","LU2039709279.SGD","LU0823426480.USD","LU0029874061.USD","LU0856984785.SGD","IE00B0JY6N72.USD","LU2488822045.USD","LU0979878070.USD","LU0140636845.USD","02269","LU0516422440.USD","LU0588546209.SGD","SG9999002463.SGD","BK1610","LU0823426308.USD","LU0359201612.USD","LU0320764599.SGD","LU0348735423.USD","LU0051755006.USD","LU1688375341.USD","LU0417516738.SGD","BK1589","LU1794554557.SGD","LU0043850808.USD","LU0326950275.SGD","LU0516422952.EUR","LU0572944931.SGD","LU3063872942.SGD","SG9999014674.SGD","LU0516422366.SGD","LU0456827905.SGD","LU0417516902.SGD","LU0052750758.USD","LU0516423091.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662172061","title":"China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2662172061","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662172061?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:28","pubTimestamp":1787912881,"startTime":"0","endTime":"0","summary":"China's Dawnrays Pharmaceutical H1 revenue falls on lower procurement pricesOverviewChina pharmaceutical maker's interim revenue fell 13.4% yr/yr on lower sales of key productsProfit attributable to o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0463099449.HKD","KURE","LU2097828557.USD","LU2242644610.SGD","LU1969619763.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","BK1583","HK0000165453.HKD","LU2488822045.USD","03737","LU1188198961.HKD","LU0244354667.USD","LU0455707207.USD","01801","BK1589","02348","BK1606","LU0326950275.SGD","BK1161","LU2097828714.EUR","LU2097828805.USD","BK1191","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066488","title":"China's Joinn Laboratories H1 Profit Jumps 1,127% on Strong Drug Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066488","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662066488?lang=en_us&edition=fundamental","pubTime":"2026-08-28 17:54","pubTimestamp":1787910858,"startTime":"0","endTime":"0","summary":"China's Joinn Laboratories H1 profit jumps 1,127% on strong drug demandOverviewChina CRO services provider's interim revenue grew 5.3% yr/yr, net income surged 1,126.8%Company attributed growth to mar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0B3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603127","LU0516422366.SGD","LU0516422952.EUR","LU0307460666.USD","01873","BK0216","LU0856984785.SGD","BK1521","LU0181495838.USD","LU0516422440.USD","IE00B0JY6N72.USD","LU0348735423.USD","LU0819121731.USD","LU1146622755.USD","LU1880383366.USD","BK1610","BK1589","LU0043850808.USD","BK1141","LU0417516738.SGD","BK0174","LU0417516902.SGD","LU0359201612.USD","LU0823426308.USD","06127","LU1242518931.SGD","LU0979878070.USD","BK0077","LU1794554557.SGD","300347","LU1720050803.USD","LU0326950275.SGD","LU0327786744.USD","LU1688375341.USD","SG9999002463.SGD","LU0320764599.SGD","LU0051755006.USD","LU0052750758.USD","LU2039709279.SGD","LU3063872942.SGD","02269","LU0039217434.USD","LU0588546209.SGD","BK0028","LU0708995583.HKD","LU0456846285.SGD","LU0572944931.SGD","LU0029874061.USD","KURE","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078065","title":"Hong Kong's Frontage Holdings H1 Profit More than Doubles on Teddy Lab Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078065","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662078065?lang=en_us&edition=fundamental","pubTime":"2026-08-28 17:43","pubTimestamp":1787910206,"startTime":"0","endTime":"0","summary":"Hong Kong's Frontage Holdings H1 profit more than doubles on Teddy Lab acquisitionOverviewHong Kong-based CRO's H1 revenue rose 17% yr/yr to $148.2 mlnNet profit for H1 more than doubled to $6.8 mlnCo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL1N44P0AU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK1521","LU0516422440.USD","LU0029874061.USD","LU1720050803.USD","BK1583","LU0043850808.USD","LU0128526141.USD","LU0516422366.SGD","SG9999002463.SGD","LU2039709279.SGD","LU0456846285.SGD","BK1141","LU0359201612.USD","LU1242518931.SGD","LU0348735423.USD","LU0516422952.EUR","LU1688375341.USD","LU1880383366.USD","LU0856984785.SGD","LU0140636845.USD","LU0588546209.SGD","LU1794554557.SGD","LU0417516902.SGD","BK1589","LU0181495838.USD","LU0819121731.USD","LU0823426308.USD","LU0039217434.USD","LU3063872942.SGD","LU0320764599.SGD","BK0174","02269","300347","BK0077","LU0051755006.USD","LU0326950275.SGD","LU0572944931.SGD","KURE","LU0979878070.USD","LU1146622755.USD","BK1610","IE00B0JY6N72.USD","BK0216","LU0307460666.USD","01521","LU0417516738.SGD","LU0708995583.HKD","LU0052750758.USD","LU0327786744.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662050237","title":"CSPC Pharmaceutical Group Stock Sheds 1.5% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2662050237","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662050237?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:32","pubTimestamp":1787905920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. shed 1.5% to 9.53 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 25584.79.The stock's fall snapped a four-day winning streak.CSPC Pharmaceutical Group Ltd. closed 18% short of its 52-week high of HK$11.63, which the company reached Sept. 9.The stock demonstrated a mixed performance when compared to some of its competitors, as Sino Biopharmaceutical Ltd. fell 0.7%, SSY Group Ltd. rose 0.4%, and United Laboratories International Holdings Ltd. fell 1.8%.Trading volume totaled 74.5 million shares, compared to the 50-day average of 104.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","LU1226288253.USD","LU1226288170.HKD","LU1226287529.USD","BK1521","IE0008368742.USD","LU0067412154.USD","IE00B5MMRT66.SGD","LU1807302812.USD","LU1008478684.HKD","KURE","SG9999004220.SGD","HK0000165453.HKD","LU1813983027.USD","LU2039709279.SGD","IE00BZ08YT58.USD","LU1152091168.USD","LU0880133367.SGD","IE00B543WZ88.USD","LU0072913022.USD","LU1951186391.HKD","LU1993786604.SGD","LU0501845795.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","LU0315179316.USD","LU0314109678.HKD","LU1226287792.SGD","LU1960683339.HKD","01093","BK1515","LU0326950275.SGD","BK1191","IE00BZ08YR35.GBP","LU1152091754.HKD","LU1328277881.USD","IE00B031HY20.USD","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662936058","title":"Akeso Says Phase III Ivonescimab-Chemo Trial in Biliary Tract Cancer Meets Overall Survival Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662936058","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662936058?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:45","pubTimestamp":1787885130,"startTime":"0","endTime":"0","summary":"Akeso says Phase III ivonescimab-chemo trial in biliary tract cancer meets overall survival endpointAkeso highlighted late-stage gains for ivonescimab, with a Phase III first-line biliary tract cancer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL6VxC1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","09926","LU0348735423.USD","LU0634319403.HKD","KURE","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","LU0348783233.USD","LU0348784397.USD","LU0561508036.HKD","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348825331.USD","LU0417516571.SGD","LU2778985437.USD","LU0417516738.SGD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU1720050803.USD","LU2399975544.HKD","LU0348827113.USD","LU0540923850.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662058969","title":"Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2662058969","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662058969?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:45","pubTimestamp":1787885100,"startTime":"0","endTime":"0","summary":"HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) (\"Akeso\" or the \"Company\") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales r","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","BK4585","LU2298322129.HKD","IE00B543WZ88.USD","ON","IE00B5MMRT66.SGD","BK1161","LU0348825331.USD","BK4211","LU2399975544.HKD","LU1983260115.SGD","BK4195","LU1720051017.SGD","LU2476274720.SGD","LU1720050803.USD","BK4135","BK4588","CNS","LU1720051108.HKD","LU0348723411.USD","ONG","LU1861214812.USD","PFS","09926","LU0561508036.HKD","LU0634319403.HKD","ONX","LU0417516902.SGD","LU0348766576.USD","LU2357305700.SGD","LU2778985437.USD","LU0348827113.USD","LU1861215975.USD","IE00BPRC5H50.USD","HCC","BK4512","LU2488822045.USD","KURE","BK4006","LU0348784397.USD","LU1861220033.SGD","LU2360107325.USD","LU1854104046.USD","LU1854103824.USD","IE00BFMHRM44.USD","BK4141","COAL","LU0417516571.SGD","LU0348735423.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145217194","title":"CMB International Lifts WUXI BIO Price Target to HK$60, Maintains \"Buy\" Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1145217194","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145217194?lang=en_us&edition=fundamental","pubTime":"2026-08-28 10:44","pubTimestamp":1787885052,"startTime":"0","endTime":"0","summary":"CMB International has released a research report highlighting WUXI BIO (02269)'s strong first-half performance, which prompted an upward revision of its full-year revenue growth guidance to 15%-18%....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","LU0359201612.USD","LU0052750758.USD","BK1141","LU0051755006.USD","LU0039217434.USD","LU0823426480.USD","LU0588546209.SGD","LU0029874061.USD","LU0348735423.USD","LU0823426308.USD","LU0856984785.SGD","KURE","LU0320764599.SGD","LU0140636845.USD","LU0456846285.SGD","LU0043850808.USD","LU0326950275.SGD","LU0979878070.USD","LU1794554557.SGD","LU0516422366.SGD","LU0456827905.SGD","LU0708995583.HKD","LU1720050803.USD","BK1610","LU0327786744.USD","LU0516423174.USD","SG9999002463.SGD","LU0516423091.SGD","LU1242518857.USD","BK1521","BK1589","IE00B0JY6N72.USD","02269","LU0307460666.USD","LU0819121731.USD","LU0516422440.USD","LU2039709279.SGD","LU0417516902.SGD","LU0359202008.SGD","LU1688375341.USD","LU0516422952.EUR","LU0181495838.USD","LU0128526141.USD","PRTO","BK1576","LU0572944931.SGD","EWH","SG9999002562.SGD","LU0348825331.USD","LU0417516738.SGD","LU3063872942.SGD","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203452","title":"Akeso's Losses Narrow in H1 as Revenue Climbs 28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203452","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203452?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:06","pubTimestamp":1787875618,"startTime":"0","endTime":"0","summary":"Akeso  reported an attributable loss of 424.2 million yuan for the first half, narrowing from a loss of 570.1 million a year earlier.Loss per share stood at 0.46 yuan, compared with 0.64 yuan in the year-ago period, according to a Thursday filing with the Hong Kong Exchange.The biotech company's revenue increased 28% year over year to 1.81 billion yuan for the six months ended June 30 from 1.41 billion yuan.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2488822045.USD","LU1961090484.USD","LU0348825331.USD","LU0348767384.USD","LU0348766576.USD","LU0561508036.HKD","LU2399975544.HKD","LU0540923850.HKD","LU0348784397.USD","KURE","LU0348783233.USD","IE00BPRC5H50.USD","LU0417516738.SGD","LU0417516902.SGD","BK1574","LU1794554557.SGD","LU2778985437.USD","09926","IE00B5MMRT66.SGD","LU2476274308.USD","LU1720050803.USD","BK1161","LU2476274720.SGD","LU0348827113.USD","LU0634319403.HKD","FCA","IE00B543WZ88.USD","LU0417516571.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662378920","title":"Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2662378920","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662378920?lang=en_us&edition=fundamental","pubTime":"2026-08-28 06:45","pubTimestamp":1787870742,"startTime":"0","endTime":"0","summary":"It's been a good week for Innovent Biologics, Inc. ( HKG:1801 ) shareholders, because the company has just released its...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/earnings-beat-innovent-biologics-inc-just-beat-analyst-forec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1801/innovent-biologics-shares/news/earnings-beat-innovent-biologics-inc-just-beat-analyst-forec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","HK0000165453.HKD","LU2097828631.EUR","LU2328871848.SGD","KURE","VGFPF","LU1969619763.USD","LU0244354667.USD","LU2097828474.EUR","BK1583","LU2242644610.SGD","BK1161","LU0502904849.HKD","FEBU","LU0455707207.USD","01801","PMDE","DECU","LU0326950275.SGD","GXDW","LU0463099449.HKD","JOYT","LU1188198961.HKD","LU2097828714.EUR","BK1589","LU2097828805.USD","LU2488822045.USD","RGLO","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662086799","title":"Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662086799","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662086799?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:51","pubTimestamp":1787842274,"startTime":"0","endTime":"0","summary":"Innovent Biologics files HKEX next-day disclosure return, issues 182,021 new sharesInnovent filed a next-day disclosure return on Aug. 27, 2026 for share issuances from option exercises.Issued 182,021","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL82CCyd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","KURE","LU1969619763.USD","01801","LU2097828805.USD","LU2328871848.SGD","LU0455707207.USD","LU2488822045.USD","LU0463099449.HKD","LU2097828474.EUR","01911","LU0326950275.SGD","LU0244354667.USD","LU2097828557.USD","LU2242644610.SGD","LU2097828631.EUR","BK1583","BK1147","BK1161","LU2097828714.EUR","LU0502904849.HKD","LU1188198961.HKD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790083","title":"Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:00","pubTimestamp":1787839249,"startTime":"0","endTime":"0","summary":"Akeso FY26 H1 net loss narrows 23.98% to RMB 447.2 million; revenue rises 27.92% to RMB 1.81 billionAkeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL34jFkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU2778985437.USD","LU0540923850.HKD","LU2476274308.USD","LU0417516571.SGD","LU1720050803.USD","LU2399975544.HKD","KURE","IE00BPRC5H50.USD","LU0348767384.USD","LU0348784397.USD","LU0417516738.SGD","09926","LU0348825331.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","LU2488822045.USD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","LU0348735423.USD","LU0417516902.SGD","LU0348766576.USD","BK1574","LU1794554557.SGD","LU0634319403.HKD","LU0348783233.USD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662980702","title":"Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662980702","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662980702?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:05","pubTimestamp":1787832345,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) has an average rating of buy and mean price target of HK$127.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2097828805.USD","LU2097828714.EUR","LU2097828631.EUR","LU2097828474.EUR","HK0000165453.HKD","LU2097828557.USD","LU0244354667.USD","BK1161","LU0463099449.HKD","LU0455707207.USD","LU2242644610.SGD","LU2328871848.SGD","01801","LU2488822045.USD","LU1188198961.HKD","LU1969619763.USD","LU0326950275.SGD","BK1589","BK1583","KURE","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662046377","title":"China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662046377","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662046377?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:40","pubTimestamp":1787830849,"startTime":"0","endTime":"0","summary":"China's CStone Pharmaceuticals H1 revenue soars on drug salesOverviewChina biopharma firm's half-year revenue rose 315% yr/yr to RMB205.1 mlnRevenue growth driven by higher pharmaceutical sales, espec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1191","LU1969619763.USD","LU2097828557.USD","LU0455707207.USD","01801","03692","BK0216","BK1583","BK1589","LU0463099449.HKD","BK1161","LU0326950275.SGD","LU2097828805.USD","LU1188198961.HKD","02616","BK1574","LU2097828474.EUR","LU0244354667.USD","688796","LU0502904849.HKD","LU2328871848.SGD","KURE","HK0000165453.HKD","LU2097828631.EUR","LU2097828714.EUR","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662457709","title":"CSPC Pharma Gets Trial Nod for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662457709","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662457709?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:05","pubTimestamp":1787828740,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","IE00B031HY20.USD","BK1515","LU0501845795.SGD","LU1226288253.USD","BK1191","LU1993786604.SGD","IE0008368742.USD","SG9999004220.SGD","LU2039709279.SGD","LU0314109678.HKD","LU1226287792.SGD","IE0008369823.USD","LU0880133367.SGD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","LU0067412154.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU1152091168.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1226287529.USD","LU1226288170.HKD","LU1960683339.HKD","LU1807302812.USD","LU0140636845.USD","LU1328277881.USD","IE00B543WZ88.USD","KURE","LU1152091754.HKD","HK0000165453.HKD","LU0072913022.USD","LU1226287875.USD","01093","LU1813983027.USD","LU0315179316.USD","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191071495","title":"CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1191071495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191071495?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826628,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its developed SYH2092 injection has received approval from China's National Medical Products Administration to proceed with clinical trials within the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287875.USD","BK1521","IBBQ","BK1515","HK0000165453.HKD","LU1226287529.USD","LU1226288253.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","01093","LU1008478684.HKD","IE00B5MMRT66.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1152091168.USD","LU0072913022.USD","LU1152091754.HKD","LU1226288170.HKD","LU1807302812.USD","IBBJ","LU0501845795.SGD","LU0314109678.HKD","BMED","LU1813983027.USD","LU0067412154.USD","PSYK","LU1993786604.SGD","IE00B543WZ88.USD","IE00BZ08YT58.USD","LU0880133367.SGD","LU0326950275.SGD","LU1328277881.USD","MDTX","LU2039709279.SGD","LU1960683339.HKD","SG9999004220.SGD","IE00B031HY20.USD","LU1226287792.SGD","LU0315179316.USD","BK1191","IE0008369823.USD","KURE","LU0140636845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703286","title":"CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703286?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825977,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2092 amylin agonist injectionCSPC won China NMPA clearance to start clinical trials of SYH2092, an amylin receptor agonist injection for obesity.Program ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL60gfrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","LU1152091168.USD","LU1807302812.USD","01093","IE00BZ08YS42.EUR","BK1515","LU0315179316.USD","LU0072913022.USD","LU2039709279.SGD","LU0880133367.SGD","LU1226287529.USD","HK0000165453.HKD","LU1008478684.HKD","LU1226288253.USD","LU1226287875.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU0501845795.SGD","LU1226288170.HKD","BK1191","IE00B031HY20.USD","LU1813983027.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU1226287792.SGD","LU1993786604.SGD","LU0314109678.HKD","LU1960683339.HKD","IE0008368742.USD","IE00BZ08YT58.USD","BK1521","LU1328277881.USD","LU1951186391.HKD","LU0140636845.USD","LU1152091754.HKD","LU0326950275.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}